209 related articles for article (PubMed ID: 27673689)
1. A Multi-Institutional Feasibility Study on the Use of Automated Screening Systems for Quality Control Rescreening of Cervical Cytology.
Sugiyama Y; Sasaki H; Komatsu K; Yabushita R; Oda M; Yanoh K; Ueda M; Itamochi H; Okugawa K; Fujita H; Tase T; Nakatani E; Moriya T
Acta Cytol; 2016; 60(5):451-457. PubMed ID: 27673689
[TBL] [Abstract][Full Text] [Related]
2. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of the AutoPap system location-guided screening.
Lee JS; Kuan L; Oh S; Patten FW; Wilbur DC
Acta Cytol; 1998; 42(1):221-6. PubMed ID: 9479344
[TBL] [Abstract][Full Text] [Related]
4. Morphologic analysis of false negative SurePath® slides using Focalpoint™ GS computer-assisted cervical screening technology: An Australian experience.
Bowditch RC; Clarke JM; Baird PJ; Greenberg ML
Diagn Cytopathol; 2015 Nov; 43(11):870-8. PubMed ID: 26174002
[TBL] [Abstract][Full Text] [Related]
5. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice.
Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ
Acta Cytol; 1998; 42(1):214-20. PubMed ID: 9479343
[TBL] [Abstract][Full Text] [Related]
6. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies.
Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
Cancer; 1997 Dec; 81(6):343-7. PubMed ID: 9438459
[TBL] [Abstract][Full Text] [Related]
7. Neural-network-assisted analysis and microscopic rescreening in presumed negative cervical cytologic smears. A comparison.
Mango LJ; Valente PT
Acta Cytol; 1998; 42(1):227-32. PubMed ID: 9479345
[TBL] [Abstract][Full Text] [Related]
8. Rescreening in gynecologic cytology. Rescreening of 8096 previous cases for current low-grade and indeterminate-grade squamous intraepithelial lesion diagnoses--a College of American Pathologists Q-Probes study of 323 laboratories.
Jones BA
Arch Pathol Lab Med; 1996 Jun; 120(6):519-22. PubMed ID: 8651851
[TBL] [Abstract][Full Text] [Related]
9. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study.
Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
Cancer; 1997 Dec; 81(6):337-42. PubMed ID: 9438458
[TBL] [Abstract][Full Text] [Related]
10. False negative rate of cervical cytologic smear screening as determined by rapid rescreening.
Renshaw AA; Bellerose B; DiNisco SA; Minter LJ; Lee KR
Acta Cytol; 1999; 43(3):344-50. PubMed ID: 10349360
[TBL] [Abstract][Full Text] [Related]
11. Liquid-based cytology for the detection of cervical intraepithelial lesions in Jimma town, Ethiopia.
Tesfaw G; Ahmed Y; Gedefaw L; Dube L; Godu S; Eshetu K; Nigussie M; Hailekiros H; Joloba M; Goba G; Abdissa A
BMC Cancer; 2020 Jul; 20(1):706. PubMed ID: 32727507
[TBL] [Abstract][Full Text] [Related]
12. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping.
Narkcham S; Mody DR; Jones A; Thrall MJ
J Am Soc Cytopathol; 2021; 10(6):558-564. PubMed ID: 34103275
[TBL] [Abstract][Full Text] [Related]
13. Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: results of a primary screening clinical trial.
Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ; Dax Taylor D
Cancer; 1999 Dec; 87(6):354-8. PubMed ID: 10603189
[TBL] [Abstract][Full Text] [Related]
14. The interpretation of high-grade squamous intraepithelial lesion on anal cytology: a comparative analysis with the cervical Papanicolaou test.
Patel AP; Schatz-Siemers NF; Dilcher TL; Goyal A
J Am Soc Cytopathol; 2020; 9(6):540-549. PubMed ID: 32800528
[TBL] [Abstract][Full Text] [Related]
15. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
16. Focused rescreening of NILM Pap slides from women ≥ 30 years of age with positive high risk HPV DNA: an enhanced quality control measure.
Sturgis CD; Schaaf MR; Tickman RJ
Diagn Cytopathol; 2013 May; 41(5):399-403. PubMed ID: 22351303
[TBL] [Abstract][Full Text] [Related]
17. A retrospective validation of the FocalPoint GS slide profiler NFR technology by analysis of interval disease outcomes compared with manual cytology.
Nuttall DS; Hillier S; Clayton HR; Savage AJ; Martin CM; O'Leary JJ
Cancer Cytopathol; 2019 Apr; 127(4):240-246. PubMed ID: 30825407
[TBL] [Abstract][Full Text] [Related]
18. Detection of HIV mRNA in routine liquid-based cytology specimens of HIV-infected women.
Brito MJ; Quintas A; Sequeira P; Alves AT; Martins C; Félix A
Cytopathology; 2021 Sep; 32(5):640-645. PubMed ID: 33914385
[TBL] [Abstract][Full Text] [Related]
19. Critical Analyses of the Introduction of Liquid-Based Cytology in a Public Health Service of the State of São Paulo, Brazil.
Longatto-Filho A; Levi JE; Martins TR; Cohen D; Cury L; Villa LL; Eluf-Neto J
Acta Cytol; 2015; 59(3):273-7. PubMed ID: 26279162
[TBL] [Abstract][Full Text] [Related]
20. Whole-Slide Imaging of Pap Cellblock Preparations Is a Potentially Valid Screening Method.
Tawfik O; Davis M; Dillon S; Tawfik L; Diaz FJ; Amin K; Fan F
Acta Cytol; 2015; 59(2):187-200. PubMed ID: 25967603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
